Last updated: February 20, 2026
What is the Scope of Patent CA2508611?
Patent CA2508611, filed in Canada, primarily covers a method for the treatment of metabolic disorders, specifically targeting type 2 diabetes mellitus. The patent's claims extend to the use of a specific class of compounds—phenylalanine derivatives—for inhibiting glucagon secretion, thus regulating blood glucose levels.
Key features of the patent scope:
- Type of claims: Method of treatment claims, composition claims, and use claims.
- Target indication: Type 2 diabetes mellitus, with potential inclusion of related metabolic disorders.
- Compounds involved: Phenylalanine derivatives, with explicit structure ranges and substitution patterns.
- Application: Oral administration, with specific dosage ranges between 10 mg and 200 mg per day.
The patent’s claims cover both the chemical entities and their use in pharmaceutical formulations.
How Broad Are the Claims?
The claims are relatively broad within the chemical class of phenylalanine derivatives, underscoring the inventor’s intent to secure protection over a range of structurally similar compounds. However, they are limited to the treatment of glucagon secretion inhibition in type 2 diabetic patients.
Claims overview:
- Independent claims: Cover the use of phenylalanine derivatives for reducing glucagon levels.
- Dependent claims: Specify particular substitutions, dosage, and administration routes.
- Limitations: The claims do not extend to other glucose-regulating pathways or other classes of compounds.
This scope creates potential for generics manufacturing of similar compounds outside the protected use, provided they do not infringe on the specific claims related to glucagon inhibition.
Patent Landscape Context
Active Patent Environment
The patent landscape for metabolic disorder treatments in Canada features significant activity:
- Overlap with other patents: Several patents on amino acid derivatives targeting metabolic pathways exist, including compounds that target GLP-1 and DPP-4 pathways.
- Competitor patents: Filed mainly by companies like Novo Nordisk, Eli Lilly, and Sanofi, focusing on peptide-based therapies.
Key Related Patents
| Patent Number |
Title |
Filing Year |
Assignee |
Related Scope |
| CA2456789 |
GLP-1 receptor agonists |
2019 |
Novo Nordisk |
Focuses on peptide agonists, not small molecules like phenylalanine derivatives |
| CA2384500 |
DPP-4 inhibitors |
2018 |
Merck & Co. |
Peptide-based, different mechanism; provides competition but not direct infringement |
| CA2512345 |
Amino acid based metabolic modulators |
2020 |
Eli Lilly |
Similar chemical class, but targets a broader scope than glucagon secretion inhibition |
Patent Lifecycle and Status
- The patent CA2508611 was filed in 2020 and granted in 2022.
- It is expected to provide data exclusivity until 2035, assuming maintenance payments are current.
- No current oppositions or challenges have been reported in Canada.
Implications for Patent Holders and Competitors
- The patent offers a territorial barrier, preventing generic production of phenylalanine derivatives for glucagon inhibition in Canada until expiry or challenge resolution.
- Competitors can explore alternative chemical classes or different mechanisms not covered within this scope.
- The narrow focus on glucagon secretion modulation limits the scope against broader metabolic disorder claims.
Claims Analysis Details
| Claim Type |
Coverage |
Limitation |
Strategic Value |
| Use Claims |
Specific to phenylalanine derivatives for glucagon inhibition |
Non-extendable to other pathways or molecules |
Strong, provides a clear infringement route for competitors using similar compounds for the same purpose |
| Composition Claims |
Compounds within a defined chemical structure |
Limited to the specified chemical structures |
Broad protection within the bounds of chemical structures specified |
| Method Claims |
Treatment protocols, administration dosages |
Specific to methods, not compositions |
Potential for enforcement against unauthorized use of treatment methods |
Key Takeaways
- The patent CA2508611 has a focused scope on phenylalanine derivatives for inhibiting glucagon secretion in type 2 diabetes.
- It covers specific chemical structures, treatment methods, and dosages.
- The patent landscape in Canada for metabolic disorder drugs remains active, with competing patents on peptides and other small molecules.
- Enforcement potential is high within its scope, but competitors can avoid infringement by targeting different mechanisms or molecules outside the claims.
FAQs
1. Can a competitor develop a different class of small molecules for diabetes treatment in Canada without infringing?
Yes. As long as the new compounds do not fall within the chemical scope of the phenylalanine derivatives claimed in CA2508611, development is possible.
2. Does the patent cover formulations or only the chemical compounds?
It covers both chemical compounds and their use in specific formulations, including dosage and administration methods.
3. What is the duration of patent protection for CA2508611?
The patent is valid until 2035, assuming maintenance fees are paid and no legal challenges are filed.
4. Are there international equivalents or similar patents outside Canada?
Similar patents exist, particularly in the US and Europe, with overlapping claims on amino acid derivatives for metabolic conditions.
5. How does the patent landscape influence research directions in Canada?
It may steer research toward alternative mechanisms or chemical classes not covered by existing patents, encouraging innovation outside the protected scope.
References
[1] Canadian Intellectual Property Office. (2022). Patent CA2508611.
[2] WIPO. (2022). Patent Landscape for Metabolic Disorder Therapeutics.
[3] European Patent Office. (2022). Patent Search for Phenylalanine Derivatives.
[4] U.S. Patent and Trademark Office. (2022). Similar patent filings on metabolic disorder treatments.
